211 related articles for article (PubMed ID: 34241562)
21. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR
J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China.
Shi Y; Xiao D; Li S; Liu S; Zhang Y
Front Pharmacol; 2023; 14():1198585. PubMed ID: 37576812
[No Abstract] [Full Text] [Related]
23. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
[TBL] [Abstract][Full Text] [Related]
24. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
Qiu Y; Zha J; Ma A; Zhou T
Gynecol Oncol; 2023 Jul; 174():175-181. PubMed ID: 37209503
[TBL] [Abstract][Full Text] [Related]
26. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E;
Lancet Oncol; 2021 May; 22(5):620-631. PubMed ID: 33743851
[TBL] [Abstract][Full Text] [Related]
27. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR
Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391
[TBL] [Abstract][Full Text] [Related]
28. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
29. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
[TBL] [Abstract][Full Text] [Related]
31. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
Zhu Y; Yang Q; Liu K; Cao H; Zhu H
J Gynecol Oncol; 2024 Jan; 35(1):e2. PubMed ID: 37477106
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by
Cheng LJ; Wong G; Chay WY; Ngeow J; Tan Y; Soon SS; Aziz MIA; Pearce F; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):441-448. PubMed ID: 33593205
[No Abstract] [Full Text] [Related]
33. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
34. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
[TBL] [Abstract][Full Text] [Related]
35. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
[TBL] [Abstract][Full Text] [Related]
36.
Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Trillsch F; Mahner S; Ataseven B; Asher R; Aryal N; Dubot C; Clamp A; Penson RT; Oza A; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; Denys H; Lowe ES; Lee CK; Pujade-Lauraine E
Gynecol Oncol; 2022 Apr; 165(1):40-48. PubMed ID: 35115180
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
Shu Y; Liu Y; He X; Ding Y; Zhang Q
Front Pharmacol; 2022; 13():818579. PubMed ID: 36034834
[No Abstract] [Full Text] [Related]
40. Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
Liu J; Hawkes C; Walder L; Spalding C; Travers K; Maiese EM; Hurteau J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1377-1387. PubMed ID: 34595950
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
